

Table of Contents

| | |
|---|----|
| PK-98-074 | 3 |
| Title Page | 3 |
| Signature Page | 3 |
| Statement Of Compliance | 4 |
| Summary | 5 |
| Key Words | 5 |
| Introduction | 6 |
| Materials and Methods | 6 |
| Chemical and Reagents | 6 |
| Test Articles | 6 |
| Formulation Manufacture | 7 |
| Formulation Analysis | 7 |
| Animals | 8 |
| Experimental | 9 |
| Tissue Bioanalysis | 9 |
| Data Analysis | 10 |
| Data and Report Handling and Storage | 10 |
| Protocol Deviations | 10 |
| Results and Discussion | 11 |
| Formulations | 11 |
| Animals | 11 |
| Bioanalysis | 12 |
| Tissue Concentrations and Pharmacokinetic Parameters | 12 |
| Conclusions | 14 |
| References | 14 |
| Tables | 16 |
| Table I. Study Design and Formulation and Dosing Data for Ocular and Systemic Absorption of Radioactivity in Rabbits... .. | 16 |
| Table II. Results of Predose, Interim, and Postdose 3H-Cyclosporine Formulation Analyses | 17 |

| | |
|--|----|
| Table III. Tissue Sample Masses from Dosed Rabbits and Limits of Quantitation (LPQ) of 3H-Radioactivity in Sampled Tissues | 18 |
| Table IV. Ocular Tissue Concentrations (n=4) in Albino Rabbits after 9 1/2 Days of Twice-Daily Ophthalmic Instillation of | 19 |
| Table V. Ocular Tissue Concentrations (n=4) in Albino Rabbits after 9 1/2 Days of Twice-Daily Ophthalmic Instillation of... .. | 20 |
| Table VI. Ocular Pharmacokinetic Parameters of 3H-Radioactivity in Albino Rabbits after 9 1/2 Days of Twice-Daily... .. | 21 |
| Table VII. Ocular Pharmacokinetic Parameters of 3H-Radioactivity in Albino Rabbits after 9 1/2 Days of Twice-Daily... .. | 22 |
| Table VIII. Ocular Pharmacokinetic Ratios in Specific Tissues after b.i.d. Instillation of 0.05% and 0.1% CsA Emulsions... .. | 23 |
| Table IX. Ocular Pharmacokinetic Parameters of Total Radioactivity in Albino Rabbits after Instillation of a Single Dose | 24 |
| Figures | 25 |
| Figure 1. Concentrations in Albino Rabbit Tears (top) and Lacrimal Gland (bottom) after 9 1/2 Days of Twice Daily... .. | 25 |
| Figure 2. Concentrations in Albino Rabbit Upper (top) and Lower (bottom) Conjunctiva after 9 1/2 Days of Twice Daily... .. | 26 |
| Figure 3. Concentrations in Albino Rabbit Cornea (top) and Sclera (bottom) after 9 1/2 Days of Twice Daily Ophthalmic... .. | 27 |
| Figure 4. Concentrations in Albino Rabbit Aqueous Humor (top) and Iris-Ciliary Body (bottom) after 9 1/2 Days of Twice... .. | 28 |
| Figure 5. Concentrations in Albino Rabbit Lens (top) and Vitreous Humor (bottom) after 9 1/2 Days of Twice Daily... .. | 29 |
| Figure 6. Concentrations in Albino Rabbit Choroid-Retina after 9 1/2 Days of Twice Daily Ophthalmic Instillation of 0.05... .. | 30 |
| Inspection Statement | 31 |

ALLERGAN
2525 Dupont Drive
Irvine, CA 92612


PHARMACOKINETICS AND DRUG METABOLISM
DEPARTMENTAL RESEARCH REPORT


Report No.: PK-98-074


Ocular Cyclosporine Distribution During 9¹/₂ Days of Dosing of 0.05 and 0.1% ³H-Cyclosporin A Emulsions to Albino Rabbit Eyes

Project name and number: Cyclosporine, 200200401081
Study number: PK-97-P019
Lab notebooks: L-1998-5707
L-1998-5709
In-life test facility: Allergan
In-life study period: October 11-December 2, 1997
Study Technicians: V. Baumgarten, S. Sirossian
Study Director: D. Small

This study was conducted in compliance with the Good Laboratory Practices (GLP), 21 Code of Federal Regulations, Part 58.

Written by:  10-29-98
D. Small, Ph.D., Senior Scientist Date
Pharmacokinetics and Drug Metabolism

Reviewed by:  10/29/98
A. Acheampong, Ph.D., Principal Scientist Date
Pharmacokinetics and Drug Metabolism

Approved by:  10-29-98
D. Tang-Liu, Ph.D., Director Date
Pharmacokinetics

STATEMENT OF COMPLIANCE

This study was conducted in accordance with Food and Drug Administration Good Laboratory Practice Regulations (21 CFR, Part 58). This report accurately reflects all raw data obtained for analysis. There were no significant deviations from Good Laboratory Practice Regulations that could have affected the quality or integrity of the study.

Study Director:



Dave Small, Ph.D., Senior Scientist

10-29-98

Date

SUMMARY

Cyclosporin A (CsA, AGN 192371) is being developed for the treatment of Sjögren's and non-Sjögren's dry eye. We investigated the absorption and disposition of CsA in blood and various ocular tissues of albino rabbits after repeated ophthalmic ^3H -CsA administration. Forty-two rabbits were dosed bilaterally with 50 μl of ^3H -CsA 0.05% (N=20) or 0.1% (N=20) ^3H -CsA emulsions twice daily for 9½ days or remained undosed (N=2) as analytical controls. Instilled doses were 0.0444 and 0.100 mg/kg/day for 0.05 and 0.1%-treated animals, respectively. Systemic blood was sampled and the tears, lacrimal gland, upper and lower bulbar conjunctiva, sclera, cornea, aqueous humor, iris-ciliary body, lens, vitreous humor, choroid-retina, and optic nerve head from each eye of two rabbits were sampled immediately before and 0.33, 1, 3, 6, 12, 24, 48, 96, and 144 hours after the last dose, after which they were analyzed by liquid scintillation analysis with or without tissue combustion. A previous study has shown that CsA is not metabolized in albino rabbit ocular tissues, and therefore radioactivity represents intact CsA.

Results in selected tissues after the last dose are shown below:

| Tissue | 0.05% CsA | | | 0.1% CsA | | |
|-------------------|-------------------|-------------------------------------|--------------------------|-------------------|-------------------------------------|--------------------------|
| | Cmax (ng-eq/g) | AUC ₀₋₁₂ (ng-eq•hr/g) | t _{1/2} (hr) | Cmax (ng-eq/g) | AUC ₀₋₁₂ (ng-eq•hr/g) | t _{1/2} (hr) |
| Lacrimal gland | 11.9 | 66.0 | ND | 15.4 | 140 | ND |
| Lower conjunctiva | 713 | 5,030 | ND | 1,920 | 15,600 | 31.8 |
| Cornea | 1,550 | 12,300 | 50.9 | 4,810 | 49,300 | 52.0 |
| Sclera | 84.5 | 848 | 39.2 | 262 | 2,710 | 40.5 |
| Lens | 18.4 | 186 | 480 | 55.2 | 529 | 271 |
| Vitreous humor | 2.93 | 22.8 | ND | 10.2 | 87.0 | ND |
| Optic nerve head | 29.3 | <146 | ND | 67.7 | <395 | ND |

ND: not determinable

Mean concentrations in tears at the first sampling time point of 20 minutes were 14,000 and 41,000 ng-eq/g after the last dose of 0.05 and 0.1% CsA, respectively. Tissue concentrations were generally flat through 12 hours, with no pronounced Cmax. AUC₀₋₁₂ in external tissues followed the rank order tears >> cornea > lower conjunctiva ~ upper conjunctiva >> sclera, and in internal tissues followed the order iris-ciliary body >> choroid-retina > lens > vitreous humor > aqueous humor. Blood concentrations were <0.694 ng-eq/g and <1.88 ng-eq/g in 0.05%- and 0.1%-treated animals, respectively.

Based on previously-reported single dose data, there was moderate accumulation in most tissues. Accumulation in lens, vitreous humor, and optic nerve head was 13- to 37-fold, although concentrations in these tissues remained less than 70 ng-eq/g. Except for lens, calculable elimination half-lives ranged from 25 to 57 hours.

The results of this study indicate that CsA concentrations were substantial in ocular surface tissues, and have long elimination half-lives that are conducive to the twice-daily dosing regimen proposed for clinical ophthalmic use. Blood concentrations were below the quantitation limit, and support the systemic safety of ophthalmic CsA administration.

KEY WORDS

Cyclosporine, cyclosporin, albino rabbit, ocular distribution

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.